Characterization of D-cyclin proteins in hematolymphoid neoplasms: Lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes

Ryan A. Metcalf, Shuchun Zhao, Matthew W. Anderson, Zhi Shun Lu, Ilana Galperin, Robert J. Marinelli, Athena M. Cherry, Izidore Lossos, Yasodha Natkunam

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

D-cyclin proteins play a central role in cell-cycle regulation and are involved in the pathogenesis of lymphomas. In mantle-cell lymphoma, the t(11;14) translocation leads to overexpression of cyclin-D1, in addition to which cyclin-D1-negative mantle-cell lymphoma that overexpress cyclin-D2 or D3 have also been described. Although cyclin-D2 and D3 have been implicated in the prognosis of specific lymphoma subtypes, a thorough characterization of D-cyclin protein expression in human hematolymphoid neoplasia has not been reported. To evaluate the tissue expression patterns of D-cyclins, particularly D2 and D3, in normal and neoplastic hematolymphoid tissues, we optimized the commercially available antibodies for D-cyclins for use on paraffin-embedded tissue and stained tissue microarrays of over 700 patient samples. Our results show that cyclin-D2 and D3 proteins are expressed in many more lymphoma subtypes than cyclin-D1. Cyclin-D1, D2 and D3 were expressed in 100, 22 and 6% of mantle-cell lymphomas and 2, 49 and 20% of diffuse large B-cell lymphomas. Fluorescence in situ hybridization studies confirmed the presence of the CCND1/IGH translocation in the majority of mantle-cell lymphoma, but not in diffuse large B-cell lymphoma that expressed cyclin-D1 protein. In addition, a subset of follicular, marginal zone, lymphoplasmacytic, lymphoblastic, classical Hodgkin, mature T-cell and natural killer cell lymphomas and acute myeloid leukemias also expressed cyclin-D2 and D3. These data support the hypothesis that dysregulation of cell-cycle control by D-cyclins contribute to the pathogenesis of hematolymphoid neoplasia, and suggest a potential role for these proteins in the prognostic and therapeutic aspects of these diseases. For diagnostic purposes, however, the expression of D-cyclin proteins should be interpreted with caution in the subclassification of lymphoma types.

Original languageEnglish
Pages (from-to)420-433
Number of pages14
JournalModern Pathology
Volume23
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

Cyclin D3
Cyclin D2
Cyclin D
Cyclin D1
Mantle-Cell Lymphoma
Lymphoma
Neoplasms
Proteins
Lymphoma, Large B-Cell, Diffuse
Cell Cycle Checkpoints
Fluorescence In Situ Hybridization
Hodgkin Disease
Acute Myeloid Leukemia
Natural Killer Cells
Paraffin
Cell Cycle
T-Lymphocytes
Antibodies

Keywords

  • CCND2
  • CCND3
  • Cyclin-D2
  • Cyclin-D3
  • Diffuse large B-cell lymphoma
  • Tissue microarray

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Metcalf, R. A., Zhao, S., Anderson, M. W., Lu, Z. S., Galperin, I., Marinelli, R. J., ... Natkunam, Y. (2010). Characterization of D-cyclin proteins in hematolymphoid neoplasms: Lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Modern Pathology, 23(3), 420-433. https://doi.org/10.1038/modpathol.2009.173

Characterization of D-cyclin proteins in hematolymphoid neoplasms : Lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. / Metcalf, Ryan A.; Zhao, Shuchun; Anderson, Matthew W.; Lu, Zhi Shun; Galperin, Ilana; Marinelli, Robert J.; Cherry, Athena M.; Lossos, Izidore; Natkunam, Yasodha.

In: Modern Pathology, Vol. 23, No. 3, 01.03.2010, p. 420-433.

Research output: Contribution to journalArticle

Metcalf, RA, Zhao, S, Anderson, MW, Lu, ZS, Galperin, I, Marinelli, RJ, Cherry, AM, Lossos, I & Natkunam, Y 2010, 'Characterization of D-cyclin proteins in hematolymphoid neoplasms: Lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes', Modern Pathology, vol. 23, no. 3, pp. 420-433. https://doi.org/10.1038/modpathol.2009.173
Metcalf, Ryan A. ; Zhao, Shuchun ; Anderson, Matthew W. ; Lu, Zhi Shun ; Galperin, Ilana ; Marinelli, Robert J. ; Cherry, Athena M. ; Lossos, Izidore ; Natkunam, Yasodha. / Characterization of D-cyclin proteins in hematolymphoid neoplasms : Lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. In: Modern Pathology. 2010 ; Vol. 23, No. 3. pp. 420-433.
@article{819629d5c5d14fdb9915413d0c0a9eaf,
title = "Characterization of D-cyclin proteins in hematolymphoid neoplasms: Lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes",
abstract = "D-cyclin proteins play a central role in cell-cycle regulation and are involved in the pathogenesis of lymphomas. In mantle-cell lymphoma, the t(11;14) translocation leads to overexpression of cyclin-D1, in addition to which cyclin-D1-negative mantle-cell lymphoma that overexpress cyclin-D2 or D3 have also been described. Although cyclin-D2 and D3 have been implicated in the prognosis of specific lymphoma subtypes, a thorough characterization of D-cyclin protein expression in human hematolymphoid neoplasia has not been reported. To evaluate the tissue expression patterns of D-cyclins, particularly D2 and D3, in normal and neoplastic hematolymphoid tissues, we optimized the commercially available antibodies for D-cyclins for use on paraffin-embedded tissue and stained tissue microarrays of over 700 patient samples. Our results show that cyclin-D2 and D3 proteins are expressed in many more lymphoma subtypes than cyclin-D1. Cyclin-D1, D2 and D3 were expressed in 100, 22 and 6{\%} of mantle-cell lymphomas and 2, 49 and 20{\%} of diffuse large B-cell lymphomas. Fluorescence in situ hybridization studies confirmed the presence of the CCND1/IGH translocation in the majority of mantle-cell lymphoma, but not in diffuse large B-cell lymphoma that expressed cyclin-D1 protein. In addition, a subset of follicular, marginal zone, lymphoplasmacytic, lymphoblastic, classical Hodgkin, mature T-cell and natural killer cell lymphomas and acute myeloid leukemias also expressed cyclin-D2 and D3. These data support the hypothesis that dysregulation of cell-cycle control by D-cyclins contribute to the pathogenesis of hematolymphoid neoplasia, and suggest a potential role for these proteins in the prognostic and therapeutic aspects of these diseases. For diagnostic purposes, however, the expression of D-cyclin proteins should be interpreted with caution in the subclassification of lymphoma types.",
keywords = "CCND2, CCND3, Cyclin-D2, Cyclin-D3, Diffuse large B-cell lymphoma, Tissue microarray",
author = "Metcalf, {Ryan A.} and Shuchun Zhao and Anderson, {Matthew W.} and Lu, {Zhi Shun} and Ilana Galperin and Marinelli, {Robert J.} and Cherry, {Athena M.} and Izidore Lossos and Yasodha Natkunam",
year = "2010",
month = "3",
day = "1",
doi = "10.1038/modpathol.2009.173",
language = "English",
volume = "23",
pages = "420--433",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Characterization of D-cyclin proteins in hematolymphoid neoplasms

T2 - Lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes

AU - Metcalf, Ryan A.

AU - Zhao, Shuchun

AU - Anderson, Matthew W.

AU - Lu, Zhi Shun

AU - Galperin, Ilana

AU - Marinelli, Robert J.

AU - Cherry, Athena M.

AU - Lossos, Izidore

AU - Natkunam, Yasodha

PY - 2010/3/1

Y1 - 2010/3/1

N2 - D-cyclin proteins play a central role in cell-cycle regulation and are involved in the pathogenesis of lymphomas. In mantle-cell lymphoma, the t(11;14) translocation leads to overexpression of cyclin-D1, in addition to which cyclin-D1-negative mantle-cell lymphoma that overexpress cyclin-D2 or D3 have also been described. Although cyclin-D2 and D3 have been implicated in the prognosis of specific lymphoma subtypes, a thorough characterization of D-cyclin protein expression in human hematolymphoid neoplasia has not been reported. To evaluate the tissue expression patterns of D-cyclins, particularly D2 and D3, in normal and neoplastic hematolymphoid tissues, we optimized the commercially available antibodies for D-cyclins for use on paraffin-embedded tissue and stained tissue microarrays of over 700 patient samples. Our results show that cyclin-D2 and D3 proteins are expressed in many more lymphoma subtypes than cyclin-D1. Cyclin-D1, D2 and D3 were expressed in 100, 22 and 6% of mantle-cell lymphomas and 2, 49 and 20% of diffuse large B-cell lymphomas. Fluorescence in situ hybridization studies confirmed the presence of the CCND1/IGH translocation in the majority of mantle-cell lymphoma, but not in diffuse large B-cell lymphoma that expressed cyclin-D1 protein. In addition, a subset of follicular, marginal zone, lymphoplasmacytic, lymphoblastic, classical Hodgkin, mature T-cell and natural killer cell lymphomas and acute myeloid leukemias also expressed cyclin-D2 and D3. These data support the hypothesis that dysregulation of cell-cycle control by D-cyclins contribute to the pathogenesis of hematolymphoid neoplasia, and suggest a potential role for these proteins in the prognostic and therapeutic aspects of these diseases. For diagnostic purposes, however, the expression of D-cyclin proteins should be interpreted with caution in the subclassification of lymphoma types.

AB - D-cyclin proteins play a central role in cell-cycle regulation and are involved in the pathogenesis of lymphomas. In mantle-cell lymphoma, the t(11;14) translocation leads to overexpression of cyclin-D1, in addition to which cyclin-D1-negative mantle-cell lymphoma that overexpress cyclin-D2 or D3 have also been described. Although cyclin-D2 and D3 have been implicated in the prognosis of specific lymphoma subtypes, a thorough characterization of D-cyclin protein expression in human hematolymphoid neoplasia has not been reported. To evaluate the tissue expression patterns of D-cyclins, particularly D2 and D3, in normal and neoplastic hematolymphoid tissues, we optimized the commercially available antibodies for D-cyclins for use on paraffin-embedded tissue and stained tissue microarrays of over 700 patient samples. Our results show that cyclin-D2 and D3 proteins are expressed in many more lymphoma subtypes than cyclin-D1. Cyclin-D1, D2 and D3 were expressed in 100, 22 and 6% of mantle-cell lymphomas and 2, 49 and 20% of diffuse large B-cell lymphomas. Fluorescence in situ hybridization studies confirmed the presence of the CCND1/IGH translocation in the majority of mantle-cell lymphoma, but not in diffuse large B-cell lymphoma that expressed cyclin-D1 protein. In addition, a subset of follicular, marginal zone, lymphoplasmacytic, lymphoblastic, classical Hodgkin, mature T-cell and natural killer cell lymphomas and acute myeloid leukemias also expressed cyclin-D2 and D3. These data support the hypothesis that dysregulation of cell-cycle control by D-cyclins contribute to the pathogenesis of hematolymphoid neoplasia, and suggest a potential role for these proteins in the prognostic and therapeutic aspects of these diseases. For diagnostic purposes, however, the expression of D-cyclin proteins should be interpreted with caution in the subclassification of lymphoma types.

KW - CCND2

KW - CCND3

KW - Cyclin-D2

KW - Cyclin-D3

KW - Diffuse large B-cell lymphoma

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=77649272309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649272309&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2009.173

DO - 10.1038/modpathol.2009.173

M3 - Article

C2 - 20062012

AN - SCOPUS:77649272309

VL - 23

SP - 420

EP - 433

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 3

ER -